Darren Carroll, Vice President Corporate Business Development, Eli Lilly
, will talk about how Lilly is pioneering a new capital efficient model to develop therapeutics by partnering with venture capital firms and leveraging resources. Rather than build complete companies around a single molecule, Lilly’s VC partners set up virtual structures that can utilize Lilly development and avoid sizable overhead. Darren will talk about this program as well as Lilly Ventures
, the company’s corporate venture capital fund, which he oversees. He will give his perspective on investment in early stage life science ventures.
Sponsored by WilmerHale
Register here: https://febspeakerseries.eventbrite.com